BOUNDLESS BIO INC Financials
This page shows BOUNDLESS BIO INC (BOLD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending and external financing dominate the reported business, with no commercial revenue base visible in these statements.
The 2024 balance-sheet repair coincided with a$89.8M financing inflow: equity moved from negative to$150.6M while liabilities fell to$55.8M . In 2025, financing was only$141K , and equity fell to$98.7M> as losses continued, showing that balance-sheet strength has been closely tied to capital raised rather than internally generated cash.
The 2025 improvement in operating cash flow, from
Capital intensity is low: capital expenditures were just
Financial Health Signals
BOUNDLESS BIO INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BOUNDLESS BIO INC passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
BOUNDLESS BIO INC reported a net loss of $58.2M while operations used $46.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
BOUNDLESS BIO INC's EBITDA was -$62.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.7% from the prior year.
BOUNDLESS BIO INC reported -$58.2M in net income in fiscal year 2025. This represents an increase of 11.0% from the prior year.
BOUNDLESS BIO INC earned -$2.60 per diluted share (EPS) in fiscal year 2025. This represents an increase of 32.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
BOUNDLESS BIO INC recorded an outflow of $47.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 25.5% from the prior year.
BOUNDLESS BIO INC held $17.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
BOUNDLESS BIO INC's ROE was -59.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 15.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
BOUNDLESS BIO INC invested $44.8M in research and development in fiscal year 2025. This represents a decrease of 18.9% from the prior year.
BOUNDLESS BIO INC invested $546K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 78.5% from the prior year.
Not reported for fiscal year 2025.
BOLD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| R&D Expenses | N/A | $44.8M-18.9% | $55.3M+29.6% | $42.6M |
| SG&A Expenses | N/A | $18.7M+3.9% | $18.0M+48.0% | $12.2M |
| Operating Income | N/A | -$63.6M+13.3% | -$73.3M-33.7% | -$54.8M |
| Income Tax | N/A | $0 | $0 | N/A |
| Net Income | N/A | -$58.2M+11.0% | -$65.4M-32.2% | -$49.4M |
| EPS (Diluted) | — | -$2.60+32.5% | -$3.85 | -$40.65 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BOLD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $157.1M-23.9% | $206.4M+58.9% | $129.9M |
| Current Assets | $109.6M-29.0% | $154.4M+24.3% | $124.2M |
| Cash & Equivalents | $17.9M-32.8% | $26.6M+12.2% | $23.7M |
| Total Liabilities | $58.4M+4.7% | $55.8M-78.3% | $257.0M |
| Current Liabilities | $12.5M+54.1% | $8.1M-13.1% | $9.4M |
| Total Equity | $98.7M-34.5% | $150.6M+218.5% | -$127.1M |
| Retained Earnings | -$259.7M-28.9% | -$201.5M-48.0% | -$136.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BOLD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$56.2M | -$46.7M+23.3% | -$60.8M-29.8% | -$46.9M |
| Capital Expenditures | $485K | $546K-78.5% | $2.5M+300.6% | $633K |
| Free Cash Flow | -$56.7M | -$47.2M+25.5% | -$63.4M-33.5% | -$47.5M |
| Investing Cash Flow | $61.1M | $37.8M+244.8% | -$26.1M+31.8% | -$38.3M |
| Financing Cash Flow | N/A | $141K-99.8% | $89.8M-8.2% | $97.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BOLD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Return on Equity | -59.0%-15.6pp | -43.4% | N/A |
| Return on Assets | -37.0%-5.4pp | -31.7%+6.4pp | -38.1% |
| Current Ratio | 8.74-10.2x | 18.98+5.7x | 13.27 |
| Debt-to-Equity | 0.59+0.2x | 0.37 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where BOUNDLESS BIO INC Ranks
Frequently Asked Questions
Is BOUNDLESS BIO INC profitable?
No, BOUNDLESS BIO INC (BOLD) reported a net income of -$58.2M in fiscal year 2025.
What is BOUNDLESS BIO INC's EBITDA?
BOUNDLESS BIO INC (BOLD) had EBITDA of -$62.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BOUNDLESS BIO INC's return on equity (ROE)?
BOUNDLESS BIO INC (BOLD) has a return on equity of -59.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BOUNDLESS BIO INC's free cash flow?
BOUNDLESS BIO INC (BOLD) recorded an outflow of $47.2M in free cash flow during fiscal year 2025. This represents a 25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BOUNDLESS BIO INC's operating cash flow?
BOUNDLESS BIO INC (BOLD) recorded an outflow of $46.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BOUNDLESS BIO INC's total assets?
BOUNDLESS BIO INC (BOLD) had $157.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BOUNDLESS BIO INC's capital expenditures?
BOUNDLESS BIO INC (BOLD) invested $546K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BOUNDLESS BIO INC spend on research and development?
BOUNDLESS BIO INC (BOLD) invested $44.8M in research and development during fiscal year 2025.
What is BOUNDLESS BIO INC's current ratio?
BOUNDLESS BIO INC (BOLD) had a current ratio of 8.74 as of fiscal year 2025, which is generally considered healthy.
What is BOUNDLESS BIO INC's debt-to-equity ratio?
BOUNDLESS BIO INC (BOLD) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BOUNDLESS BIO INC's return on assets (ROA)?
BOUNDLESS BIO INC (BOLD) had a return on assets of -37.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BOUNDLESS BIO INC's Piotroski F-Score?
BOUNDLESS BIO INC (BOLD) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BOUNDLESS BIO INC's earnings high quality?
BOUNDLESS BIO INC (BOLD) reported a net loss of $58.2M while operations used $46.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.